Abstract
This study attempts to identify and validate biomarkers that can be used to monitor recurrence after LUAD surgery. We downloaded lung adenocarcinoma data from the TCGA database and selected postoperative recurrence samples, and then performed WGCNA analysis to find key co-expression gene modules. Enrichment analysis of key gene modules was also performed using the DAVID database. Finally, we performed a survival analysis of the most interesting biomarker UPK2 obtained from the TCGA analysis in the Oncomine database and evaluated its impact on prognosis. Using WGCNA analysis, we obtained 39 gene modules, of which the purple module was most associated with recurrence. Among them, UPK2, KLHDC3, GALR2 and TYRP1 occupied a central position in the co-expression network which were also significantly correlated with the survival of patients. We collected 132 blood samples from patients with early-stage lung adenocarcinoma who were tested the expression level of free UPK2 in the plasma. The expression of UPK2 relative to GADPH in non-relapsed patients was 0.1623, and in relapsed patients, it was 0.2763. ROC was used to evaluate the effectiveness of free UPK2 mRNA in the blood for monitoring postoperative recurrence, with an AUC of 0.767 and a 95% confidence interval of 0.675–0.858. At the same time, patients with high expression of free UPK2 mRNA had significantly poorer survival than those with low expression of UPK2. The expression level of free UPK2 mRNA in plasma has the potential as an indicator of postoperative recurrence in patients with early LUAD.
Introduction
Lung adenocarcinoma (LUAD) is the most prevalent subtype of non-small cell lung cancer. Despite advancements in surgical resection and adjuvant therapies for early-stage patients, postoperative recurrence remains a significant hurdle, with 5-year survival rates ranging between 50% and 70%. Recurrence is often driven by residual cancer cells that escape initial treatment. Current monitoring protocols rely heavily on imaging techniques like CT scans, which often detect recurrence only after a substantial tumor mass has formed.
There is a pressing clinical need for minimally invasive, reliable molecular biomarkers that can detect recurrence earlier. Liquid biopsies, which analyze biomarkers in the blood, offer a promising solution. This study explores the potential of cell-free UPK2 mRNA as a novel blood-based biomarker for monitoring LUAD recurrence.
Methods
The study employed a dual-phase approach: computational discovery followed by clinical validation.
Bioinformatics Discovery
Transcriptome data from 24 relapsed LUAD patients were retrieved from The Cancer Genome Atlas (TCGA). Weighted Gene Co-expression Network Analysis (WGCNA) was performed to identify gene modules correlated with postoperative recurrence. A "purple" module showed the strongest association. Hub genes within this module were identified based on their connectivity in the co-expression network.
Survival Analysis and Clinical Validation
Candidate hub genes were cross-referenced with the Oncomine database to assess their prognostic value. For clinical validation, 132 blood samples were collected from 105 early-stage LUAD patients (35 relapsed, 70 non-relapsed) treated at Shanghai Changhai Hospital. Cell-free mRNA was extracted from plasma, and UPK2 expression levels were quantified using RT-qPCR relative to a GAPDH control.
Results
Identification of Hub Genes
WGCNA identified 39 distinct gene modules. The purple module was most significantly associated with recurrence. Within this module, four genes—UPK2, KLHDC3, GALR2, and TYRP1—emerged as central hub genes with significant correlations to patient survival.
Clinical Performance of UPK2
The clinical cohort analysis confirmed the prognostic significance of UPK2. The mean relative expression of cell-free UPK2 mRNA was significantly higher in patients who experienced recurrence (0.2763) compared to those who did not (0.1623, $P < 0.001$).
Receiver Operating Characteristic (ROC) analysis demonstrated that plasma UPK2 levels could effectively distinguish between relapsed and non-relapsed patients, with an Area Under the Curve (AUC) of 0.767 (95% CI: 0.675–0.858). Furthermore, longitudinal monitoring revealed that UPK2 levels spiked specifically at the time of relapse within individual patients.
Discussion
UPK2, traditionally a specific marker for bladder cancer, appears to be a potent indicator of recurrence in LUAD. This study demonstrates that cell-free mRNA, despite its inherent fragility, can serve as a robust clinical biomarker in liquid biopsies.
While the results are promising, the study is limited by its single-center design and relatively small sample size. Future research should focus on larger, multi-center cohorts and investigate the biological mechanisms driving UPK2 expression in lung tissue. Understanding these mechanisms could lead to the development of UPK2-targeted therapies for LUAD.
Summary updated